$CNSP
CNS Pharmaceuticals, Inc.

2024 Q2 Form 10-K Financial Statement

#000168316824002032 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.412M $1.108M $4.770M
YoY Change 19.64% -48.54% -20.07%
% of Gross Profit
Research & Development $1.117M $4.272M $14.10M
YoY Change -60.76% 27.54% 51.56%
% of Gross Profit
Depreciation & Amortization $750.00 $950.00 $4.130K
YoY Change -25.0% -60.08% -64.87%
% of Gross Profit
Operating Expenses $2.528M $5.379M $18.87M
YoY Change -37.2% -2.23% 23.57%
Operating Profit -$2.528M -$18.87M
YoY Change -37.2% 23.57%
Interest Expense -$2.610K $4.120K $13.88K
YoY Change -171.51% -278.35% 97.52%
% of Operating Profit
Other Income/Expense, Net -$2.618K $13.88K
YoY Change -163.05% -297.55%
Pretax Income -$2.531M -$5.375M -$18.85M
YoY Change -37.07% -2.34% 23.42%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.531M -$5.375M -$18.85M
YoY Change -37.07% -2.34% 23.42%
Net Earnings / Revenue
Basic Earnings Per Share -$6.72 -$5.00
Diluted Earnings Per Share -$6.72 -$1.06 -$5.00
COMMON SHARES
Basic Shares Outstanding 10.63M shares 5.249M shares 3.767M shares
Diluted Shares Outstanding 376.6K shares 3.767M shares

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.492M $548.7K $548.7K
YoY Change -65.14% -94.54% -94.54%
Cash & Equivalents $1.492M $548.7K $548.7K
Short-Term Investments
Other Short-Term Assets $653.8K $1.042M $1.042M
YoY Change -63.51% -58.46% -58.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.145M $1.591M $1.591M
YoY Change -64.66% -87.34% -87.34%
LONG-TERM ASSETS
Property, Plant & Equipment $3.553K $4.930K $4.930K
YoY Change 5.06% -12.96% -12.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.3K $104.8K $104.8K
YoY Change -15.08% -78.3% -78.3%
Total Long-Term Assets $323.9K $109.7K $109.7K
YoY Change -14.9% -77.55% -77.55%
TOTAL ASSETS
Total Short-Term Assets $2.145M $1.591M $1.591M
Total Long-Term Assets $323.9K $109.7K $109.7K
Total Assets $2.469M $1.701M $1.701M
YoY Change -61.73% -86.97% -86.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.640M $5.832M $5.832M
YoY Change 85.95% 58.4% 58.4%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $123.3K $300.8K $300.8K
YoY Change -25.93% -33.13% -26.63%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.763M $6.133M $6.133M
YoY Change 69.19% 24.65% 24.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.763M $6.133M $6.133M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.763M $6.133M $6.133M
YoY Change 69.19% 24.65% 24.65%
SHAREHOLDERS EQUITY
Retained Earnings -$75.64M -$69.57M
YoY Change 26.77% 37.17%
Common Stock $1.443K $6.214K
YoY Change -65.15% 284.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.294M -$4.432M -$4.432M
YoY Change
Total Liabilities & Shareholders Equity $2.469M $1.701M $1.701M
YoY Change -61.73% -86.97% -86.97%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.531M -$5.375M -$18.85M
YoY Change -37.07% -2.34% 23.42%
Depreciation, Depletion And Amortization $750.00 $950.00 $4.130K
YoY Change -25.0% -60.08% -64.87%
Cash From Operating Activities -$1.650M -$2.536M -$14.14M
YoY Change -51.5% 10.02% 33.93%
INVESTING ACTIVITIES
Capital Expenditures $2.160K $3.900K
YoY Change -11.8%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.160K -$3.900K
YoY Change -11.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.076M
YoY Change -68.35%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.327M 2.178M 4.637M
YoY Change -9.52% -59.17% -70.3%
NET CHANGE
Cash From Operating Activities -1.650M -2.536M -14.14M
Cash From Investing Activities -2.160K -3.900K
Cash From Financing Activities 2.327M 2.178M 4.637M
Net Change In Cash 676.3K -360.8K -9.507M
YoY Change -181.36% -111.92% -288.22%
FREE CASH FLOW
Cash From Operating Activities -$1.650M -$2.536M -$14.14M
Capital Expenditures $2.160K $3.900K
Free Cash Flow -$2.539M -$14.14M
YoY Change 10.11% 33.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001729427
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Registrant Name
EntityRegistrantName
CNS Pharmaceuticals, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2318545
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 West Loop South
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
CY2023 dei City Area Code
CityAreaCode
800
CY2023 dei Local Phone Number
LocalPhoneNumber
946-9185
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
8780000 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10634932 shares
CY2023 dei Auditor Firm
AuditorFirmId
206
CY2023 dei Auditor Name
AuditorName
MaloneBailey, LLP
CY2023 dei Auditor Location
AuditorLocation
Houston, Texas
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
548721 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10055407 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
202859 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
839590 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2509238 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1591170 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
12564645 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
104750 usd
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
482806 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4933 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5664 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
109683 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
488470 usd
CY2023Q4 us-gaap Assets
Assets
1700853 usd
CY2022Q4 us-gaap Assets
Assets
13053115 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5832162 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4510291 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
300806 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
409968 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6132968 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4920259 usd
CY2023Q4 us-gaap Liabilities
Liabilities
6132968 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4920259 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6214598 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6214598 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1617325 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1617325 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6214 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1617 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65128574 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58846916 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69566903 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50715677 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4432115 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1700853 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13053115 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4769502 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5967052 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9300055 usd
CY2023 us-gaap Interest Income Operating
InterestIncomeOperating
27687 usd
CY2022 us-gaap Interest Income Operating
InterestIncomeOperating
0 usd
CY2023 us-gaap Interest Expense
InterestExpense
13805 usd
CY2022 us-gaap Interest Expense
InterestExpense
7027 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13882 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7027 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-18851226 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-15274134 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.22
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.22
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3767372 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1361737 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3767372 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1361737 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6163197 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16038093 usd
CY2022 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
2734 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1202966 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-15274134 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2317599 usd
CY2023 CNSP Stock Issued For Exercise Of Warrants Net
StockIssuedForExerciseOfWarrantsNet
2961239 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1007417 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-18851226 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4432115 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-18851226 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-15274134 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1007417 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1202966 usd
CY2023 us-gaap Depreciation
Depreciation
4134 usd
CY2022 us-gaap Depreciation
Depreciation
11756 usd
CY2023 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
0 usd
CY2022 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
334138 usd
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-498 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3111 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2377275 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-860451 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1321871 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2303897 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14140031 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10557815 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3901 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4422 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3901 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4422 usd
CY2023 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
202859 usd
CY2022 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
-0 usd
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
438733 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
427700 usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2961239 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2734 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2317599 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16038093 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4637246 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15613127 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9506686 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5050890 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10055407 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5004517 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
548721 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10055407 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
13805 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
8094 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023 CNSP Prepaid Expense Financed With Note Payable
PrepaidExpenseFinancedWithNotePayable
329571 usd
CY2022 CNSP Prepaid Expense Financed With Note Payable
PrepaidExpenseFinancedWithNotePayable
449874 usd
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80E_eus-gaap--NatureOfOperations_zNABsr32DS0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 – <span id="xdx_82A_zOuRGlIajAGe">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 25, 2022, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30. The reverse stock split became effective on November 28, 2022 on a 1-for-30 basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_z6k7xIYDMSej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_861_zwXB74poZOY1">Use of Estimates in Financial Statement Presentation</span> -</b> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
298721 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0338 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0437 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.1413 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1809 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M14D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
8217 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-thirty (1:30) reverse stock split of the Company’s common stock and the filing of the Amendment to effectuate the reverse split. The reverse stock split became effective on November 28, 2022 on a 1-for-30 basis without any change in the par value per share, which remained at $0.001.
CY2023 CNSP Nonaccountable Expense Allowance
NonaccountableExpenseAllowance
50000 usd
CY2023 us-gaap Legal Fees
LegalFees
100000 usd
CY2023 CNSP Clearing Fees
ClearingFees
15950 usd
CY2022 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
334138 usd
CY2023 CNSP Fair Value Of Common Stock On Measurement Date
FairValueOfCommonStockOnMeasurementDate
$1.00 to $2.40 per share
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8217 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
5571694 usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2961239 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2734 usd
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
800000 usd
CY2023Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
2500000 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3959000 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3206000 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
118000 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-194000 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-4077000 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3012000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6672000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8603000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
873000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
715000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
5420000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
0 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
198000 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
628000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12767000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8690000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
31771000 usd
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-002032-index-headers.html Edgar Link pending
0001683168-24-002032-index.html Edgar Link pending
0001683168-24-002032.txt Edgar Link pending
0001683168-24-002032-xbrl.zip Edgar Link pending
cnsp-20231231.xsd Edgar Link pending
cnspharma_ex2301.htm Edgar Link pending
cnspharma_ex3101.htm Edgar Link pending
cnspharma_ex3102.htm Edgar Link pending
cnspharma_ex3201.htm Edgar Link pending
cnspharma_ex3202.htm Edgar Link pending
cnspharma_ex9700.htm Edgar Link pending
cnspharma_i10k-123123.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
cnsp-20231231_def.xml Edgar Link unprocessable
cnsp-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cnspharma_i10k-123123_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnsp-20231231_cal.xml Edgar Link unprocessable
cnsp-20231231_pre.xml Edgar Link unprocessable